• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CORPORATION IMUFLEX BLOOD BAG SYSTEM; IMUFLEX WB-RP BLOOD BAG SYSTEM WITH LR FILTER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CORPORATION IMUFLEX BLOOD BAG SYSTEM; IMUFLEX WB-RP BLOOD BAG SYSTEM WITH LR FILTER Back to Search Results
Catalog Number 1BBWGQ506A2
Device Problems Restricted Flow rate (1248); Defective Component (2292); High Test Results (2457); Filtration Problem (2941)
Patient Problem No Patient Involvement (2645)
Event Date 09/08/2019
Event Type  malfunction  
Manufacturer Narrative
Investigation is in process.A follow-up report will be provided.
 
Event Description
The customer reported elevated white blood cell (wbc) content in a filtered whole blood unit.There was not a transfusion recipient or patient involved at the time of whole blood processing,therefore no patient information is reasonably known at the time of the event.Donor unit #: (b)(6).
 
Manufacturer Narrative
This report is being filed to provide additional information in h.3, h.6 and h.10.Investigation: one filter from the collection set was returned for evaluation.The leukoreduction filter was tested for flow rate and air leaks.A fast flow rate of 47ml/min was noted, and it was confirmed there were no air leaks.The filter was disassembled to observe the appearance of filter membranes and noticed creases in the filter membranes of the filter.The creases in the filter were not different from those in conforming products and in the filter membranes and aggregation was observed in the second filter membranes.The manufacturing records, test records, and inspection records were reviewed for abnormalities and none were found.The records regarding the particulate removal rates of the filter membranes were reviewed.All membranes conformed to established specification.Shipping testing was performed on the reserve samples from the reported lot number.The reserve samples were also visually examined, and the solution volume and solution composition were tested with no abnormalities noted.All product conformed to the established specification.Root cause: based on the available information, it cannot be ruled out that the higher-than- expected wbc content in the whole blood product could be due to an occlusion, we noticed that the third and fourth filter membranes from the inflow side of the filter were locally dyed dark with toluidine blue.The investigation showed aggregation on the second filter membrane.Therefore, occlusion may have occurred, and blood may have been filtered by the filter area which was smaller than usual and the linear speed (flow rate per unit area) increased, and then leukocyte leakage occurred.Investigation results showed that aggregation is observed in some of the filter membranes in each filter inferring that after the filtration starts ,the excessive aggregates in the donation bags flowed into the filters and caused clogging on the inflow side of the filter layers.There is also a possibility that the blood may have been separated in the donation bags,as it is observed that separated blood did not disappear even after being agitated prior to filtration.As a result, the blood with high flow resistance flowed into the filters and occluded the inflow side of the filter layers causing leukocyte leakage by the increase in the linear speed.The instructions for use of product state provide a caution to not squeeze or apply pressure to the filter while it is attached to the bag containing the filtered blood and also to clamp the blood-filled tubing before blood enters the filter in order to avoid leukocyte leakage.Correction:in order to reduce the risk of formation of blood aggregation,it is recommended that donation bag needs to be inverted several times immediately after blood collection to ensure that blood and anticoagulant became well-mixed and to reduce the risk of slow blood flow the bag should be fully agitated before the start of filtration for the even disperse of the separated blood components.
 
Manufacturer Narrative
This report is being filed to provide corrected information in h.3.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMUFLEX BLOOD BAG SYSTEM
Type of Device
IMUFLEX WB-RP BLOOD BAG SYSTEM WITH LR FILTER
Manufacturer (Section D)
TERUMO CORPORATION
fujinomiya
MDR Report Key9239366
MDR Text Key182233177
Report Number9681839-2019-00064
Device Sequence Number1
Product Code CAK
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Type of Report Initial,Followup,Followup
Report Date 10/25/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date01/31/2021
Device Catalogue Number1BBWGQ506A2
Device Lot Number180806AF
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer10/04/2019
Was the Report Sent to FDA? Yes
Initial Date Manufacturer Received 09/30/2019
Initial Date FDA Received10/25/2019
Supplement Dates Manufacturer Received12/09/2019
12/09/2019
Supplement Dates FDA Received12/06/2019
12/09/2019
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other;
-
-